AR109773A1 - Composición que comprende compuesto antibiótico y un compuesto heterocíclico y su uso para prevenir o tratar infecciones bacterianas - Google Patents
Composición que comprende compuesto antibiótico y un compuesto heterocíclico y su uso para prevenir o tratar infecciones bacterianasInfo
- Publication number
- AR109773A1 AR109773A1 ARP170102731A ARP170102731A AR109773A1 AR 109773 A1 AR109773 A1 AR 109773A1 AR P170102731 A ARP170102731 A AR P170102731A AR P170102731 A ARP170102731 A AR P170102731A AR 109773 A1 AR109773 A1 AR 109773A1
- Authority
- AR
- Argentina
- Prior art keywords
- nq1q2
- different
- nq1c
- nhq3
- independently represents
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003115 biocidal effect Effects 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 abstract 1
- 108010078777 Colistin Proteins 0.000 abstract 1
- 108010013198 Daptomycin Proteins 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- -1 Sinercid Chemical compound 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- KLFSEZJCLYBFKQ-WXYNYTDUSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCC1=CC(=O)C(O)=CN1O KLFSEZJCLYBFKQ-WXYNYTDUSA-N 0.000 abstract 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 abstract 1
- 229960003022 amoxicillin Drugs 0.000 abstract 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229960003644 aztreonam Drugs 0.000 abstract 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229960002100 cefepime Drugs 0.000 abstract 1
- 229950000788 cefiderocol Drugs 0.000 abstract 1
- DBPPRLRVDVJOCL-FQRUVTKNSA-N cefiderocol Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1(CCNC(=O)C=2C(=C(O)C(O)=CC=2)Cl)CCCC1 DBPPRLRVDVJOCL-FQRUVTKNSA-N 0.000 abstract 1
- 229960002129 cefixime Drugs 0.000 abstract 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 abstract 1
- 229960004261 cefotaxime Drugs 0.000 abstract 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 abstract 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 abstract 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 abstract 1
- 229960005090 cefpodoxime Drugs 0.000 abstract 1
- 229940036735 ceftaroline Drugs 0.000 abstract 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 abstract 1
- 229960004755 ceftriaxone Drugs 0.000 abstract 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 abstract 1
- 229960005091 chloramphenicol Drugs 0.000 abstract 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 1
- 229960003405 ciprofloxacin Drugs 0.000 abstract 1
- 229960002227 clindamycin Drugs 0.000 abstract 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 abstract 1
- 229960003346 colistin Drugs 0.000 abstract 1
- 229960005484 daptomycin Drugs 0.000 abstract 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 1
- 229960003276 erythromycin Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229960002260 meropenem Drugs 0.000 abstract 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 abstract 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 abstract 1
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002292 piperacillin Drugs 0.000 abstract 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 abstract 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 abstract 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 abstract 1
- 229960001225 rifampicin Drugs 0.000 abstract 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005256 sulbactam Drugs 0.000 abstract 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229960004089 tigecycline Drugs 0.000 abstract 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Composición que comprende: por lo menos un antibiótico seleccionado de: Amoxicilina, Amikacina Aztreonam, Ciprofloxacina, Clindamicina, Cloranfenicol, Colistina, Cefpiroma, Ceftriaxona, Cefotaxima, Daptomicina, Eritromicina, Cefepima, Cefixima, Fosfomicina, Cefuroxima, lmipenem, Linezolid, Meropenem, Piperacilina, Cefpodoxima, Rifampicina, Sinercid, Tigeciclina, Vancomicina, Sulbactama, Ceftarolina, Cefiderocol (S-649266) o BAL30072; y por lo menos un compuesto de fórmula (1), donde: R se selecciona de -SO₃H o CF₂CO₂H; R¹ se selecciona de H, CH₂-NH₂, CONH₂ o un heteroarilo de 5 miembros que comprende por lo menos dos nitrógenos; A-B es un resto de fórmula (2) o A es CH₂ y B es C=NOR⁴; R² es un átomo de hidrógeno o un heterociclo de 4 a 10 miembros saturado, parcial o totalmente insaturado o aromático, que comprende por lo menos un átomo de nitrógeno, no sustituido o sustituido con uno o más T¹, preferentemente no sustituido; R³ es H, u oxazolilo; o R² y R³ junto con el átomo de carbono al que están unidos forman un ciclo seleccionado de: los restos de fórmula (3) o fórmula (4), donde Y es S u O, preferentemente S, y R⁵ es C₂₋₃-alquilo-NH₂; R⁴ es -(CH₂)₂NH₂ o -CH₂CONH₂; T¹, idéntico o diferente, representa de manera independiente un átomo de flúor; -(CH₂)ₘOQ¹; -(CH₂)ₘ-CN; -(CH₂)ₘ-OC(O)Q¹; -(CH₂)ₘ-C(O)OQ¹; -(CH₂)ₘ-OC(O)OQ¹; -(CH₂)ₘ-OC(O)NQ¹Q²; -(CH₂)ₘ-C(O)NQ¹Q²; -(CH₂)ₘ-C(O)ONQ¹Q²; -(CH₂)ₘ-C(O)NQ¹OQ²; -(CH₂)ₘ-C(O)NQ¹-NQ¹Q²; -(CH₂)ₘ-NQ¹C(O)Q²; -(CH₂)ₘ-NQ¹S(O)₂NQ¹Q²; -(CH₂)ₘ-NQ¹S(O)₂Q²; -(CH₂)ₘ-S(O)₂NQ¹Q²; -(CH₂)ₘ-NQ¹C(O)OQ²; -(CH₂)ₘ-NQ¹C(O)NQ¹Q²; -(CH₂)ₘ-NQ¹Q²; -(CH₂)ₘ-NH-C(NHQ³)=NQ⁴; -(CH₂)ₘ-NH-CH=NQ³; -(CH₂)ₘ-C(NHQ³)=NQ⁴; -(X)-(CH₂)ₚOQ¹; -(X)-(CH₂)ₙ-CN; -(X)-(CH₂)ₚ-OC(O)Q¹; -(X)-(CH₂)ₙ-C(O)OQ¹; -(X)-(CH₂)ₚ-OC(O)OQ¹; -(X)-(CH₂)ₚ-OC(O)NQ¹Q²; -(X)-(CH₂)ₙ-C(O)NQ¹Q²; -(X)-(CH₂)ₙ-C(O)ONQ¹Q²; -(X)-(CH₂)ₙ-C(O)NQ¹OQ²; -(X)-(CH₂)ₙ-C(O)NQ¹-NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹C(O)Q²; -(X)-(CH₂)ₚ-NQ¹S(O)₂NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹S(O)₂Q²; -(X)-(CH₂)ₚ-S(O)₂NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹C(O)OQ²; -(X)-(CH₂)ₚ-NQ¹C(O)NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹Q²; -(X)-(CH₂)ₚ-NH-C(NHQ³)=NQ⁴; -(X)-(CH₂)ₚ-NH-CH=NQ³; -(X)-(CH₂)ₙ-C(NHQ³)=NQ⁴; -C(O)-(CH₂)ₙOQ¹; -C(O)-(CH₂)ₙ-CN; -C(O)-(CH₂)ₙ-OC(O)Q¹; -C(O)-(CH₂)ₙ-C(O)OQ¹; -C(O)-(CH₂)ₙ-OC(O)OQ¹; -C(O)-(CH₂)ₙ-OC(O)NQ¹Q²; -C(O)-(CH₂)ₙ-C(O)NQ¹Q²; -C(O)-(CH₂)ₙ-C(O)ONQ¹Q²; -C(O)-(CH₂)ₙ-C(O)NQ¹OQ²; -C(O)-(CH₂)ₙ-C(O)NQ¹-NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹C(O)Q²; -C(O)-(CH₂)ₙ-NQ¹S(O)₂NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹S(O)₂Q²; -C(O)-(CH₂)ₙ-S(O)₂NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹C(O)OQ²; -C(O)-(CH₂)ₙ-NQ¹C(O)NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹Q²; -C(O)-(CH₂)ₙ-NH-C(NHQ³)=NQ⁴; -C(O)-(CH₂)ₙ-NH-CH=NQ³; -C(O)-(CH₂)ₙ-C(NHQ³)=NQ⁴, o T¹, idéntico o diferente, representa de manera independiente un -(CH₂)ₘ-(heterociclo saturado, parcial o totalmente insaturado o aromático, de 4, 5 ó 6 miembros), no sustituido o sustituido con uno o más T²; -(X)-(CH₂)ₘ-(heterociclo saturado, parcial o totalmente insaturado o aromático, de 4, 5 ó 6 miembros); C₁₋₃-alquilo; C₁₋₃-fluoroalquilo; -(X)-C₁₋₃-alquilo; -(X)-C₁₋₃-fluoroalquilo; -(CH₂)ₘ-C₃₋₆-cicloalquilo; -(X)-(CH₂)ₘ-C₃₋₆-cicloalquilo; -(CH₂)ₘ-C₃₋₆-ciclofluoroalquilo; -(X)-(CH₂)ₘ-C₃₋₆-ciclofluoroalquilo; -C(O)-(CH₂)ₘ-(heterociclo saturado, parcial o totalmente insaturado o aromático, de 4, 5 ó 6 miembros); -C(O)-C₁₋₃-alquilo; -C(O)-C₁₋₃-fluoroalquilo; -C(O)O-C₁₋₃-fluoroalquilo; -C(O)-(CH₂)ₘ-C₃₋₆-cicloalquilo; -C(O)-(CH₂)ₘ-C₃₋₆-cicloalquilo; -C(O)-(CH₂)ₘ-C₃₋₆-ciclofluoroalquilo; -C(O)-(CH₂)ₘ-C₃₋₆-ciclofluoroalquilo; Q¹ y Q², idéntico o diferente, representan de manera independiente un átomo de hidrógeno; -(CH₂)ʳ-NHQ³; -(CH₂)ʳ-NH-C(NHQ³)=NQ⁴; -(CH₂)ʳ-NH-CH=NQ³; (CH₂)ₙ-C(NHQ³)=NQ⁴; -(CH₂)ʳ-OQ³; -(CH₂)ₙ-CONHQ³; o un C₁₋₃-alquilo no sustituido o sustituido con uno o más T²; C₁₋₃-fluoroalquilo; (CH₂)ₘ-(heterociclo de 4, 5 ó 6 miembros saturado, parcial o totalmente insaturado o aromático que comprende por lo menos un átomo de nitrógeno); o Q¹, Q² y el átomo de nitrógeno al cual están enlazados, forman juntos un heterociclo de 4, 5 ó 6 miembros que comprende 1, 2 ó 3 heteroátomos, no sustituido o sustituido con uno o más T², saturado o parcialmente insaturado; Q³ y Q⁴, idéntico o diferente, representan de manera independiente un átomo de hidrógeno o C₁₋₃-alquilo; T², idéntico o diferente, representa de manera independiente -OH; -NH₂; -CONH₂; m, idéntico o diferente, representa de manera independiente 0, 1, 2 ó 3; n, idéntico o diferente, representa de manera independiente 1, 2 ó 3; p, idéntico o diferente, representa de manera independiente 2 ó 3; r es 1, 2 ó 3 cuando el (CH₂)ʳ, está ligado directamente a un átomo de carbono o 2 ó 3, de otra forma, preferentemente r es 2 ó 3; X, idéntico o diferente, representa de manera independiente O; S; S(O); S(O)₂ o N(Q³); por lo menos uno de R² y R³ es diferente de H, y R² y R³ no son simultáneamente H, y por lo menos uno de R¹, R², R³ es diferente de H; y un racemato, un enantiómero, un diastereoisómero, un isómero geométrico o una sal farmacéuticamente aceptable del compuesto de fórmula (1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306260.7A EP3300736B1 (en) | 2016-09-30 | 2016-09-30 | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109773A1 true AR109773A1 (es) | 2019-01-23 |
Family
ID=57130330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102731A AR109773A1 (es) | 2016-09-30 | 2017-09-29 | Composición que comprende compuesto antibiótico y un compuesto heterocíclico y su uso para prevenir o tratar infecciones bacterianas |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200024278A1 (es) |
EP (1) | EP3300736B1 (es) |
AR (1) | AR109773A1 (es) |
TW (1) | TW201815390A (es) |
WO (1) | WO2018060484A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3604315A1 (en) * | 2018-07-30 | 2020-02-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
WO2020184399A1 (ja) * | 2019-03-08 | 2020-09-17 | 塩野義製薬株式会社 | 抗菌用医薬組成物 |
CN115073458A (zh) * | 2022-07-04 | 2022-09-20 | 山东致泰医药技术有限公司 | 一种阿维巴坦钠的制备方法 |
CN115236236A (zh) * | 2022-07-26 | 2022-10-25 | 上海市食品药品检验研究院 | 一种利奈唑胺及其制剂中对映异构体的分离分析方法 |
US20240325299A1 (en) | 2023-03-29 | 2024-10-03 | King Faisal University | Combination treatment for antibiotic resistant infections |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
WO2013181741A1 (en) | 2012-06-04 | 2013-12-12 | Elkimia | Imino compounds as protecting agents against ultraviolet radiations |
WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
US10072006B2 (en) * | 2015-03-31 | 2018-09-11 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
WO2016156346A1 (en) * | 2015-03-31 | 2016-10-06 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
EP3277277B1 (en) * | 2015-04-03 | 2021-01-06 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
RU2741496C2 (ru) * | 2015-05-07 | 2021-01-26 | Мутабилис | Гетероциклические соединения и их применение в лечении или предотвращении бактериальных инфекций |
EP3091018A1 (en) * | 2015-05-07 | 2016-11-09 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
-
2016
- 2016-09-30 EP EP16306260.7A patent/EP3300736B1/en active Active
-
2017
- 2017-09-29 US US16/338,193 patent/US20200024278A1/en not_active Abandoned
- 2017-09-29 TW TW106133610A patent/TW201815390A/zh unknown
- 2017-09-29 WO PCT/EP2017/074883 patent/WO2018060484A1/en active Application Filing
- 2017-09-29 AR ARP170102731A patent/AR109773A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20200024278A1 (en) | 2020-01-23 |
TW201815390A (zh) | 2018-05-01 |
WO2018060484A1 (en) | 2018-04-05 |
EP3300736A1 (en) | 2018-04-04 |
EP3300736B1 (en) | 2021-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109773A1 (es) | Composición que comprende compuesto antibiótico y un compuesto heterocíclico y su uso para prevenir o tratar infecciones bacterianas | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
DOP2017000310A (es) | Inhibidores de metalo-beta-lactamasa | |
AR092503A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
CU24393B1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
CL2009000023A1 (es) | Compuestos derivados de heterociclos de nitrogeno y azufre, moduladores de beta-amiloide; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer, angiopatia amiloide cerebral, hemorragia cerebral, demencia multiinfarto, demencia pugilistica o sindrome de down. | |
MX2016012984A (es) | Derivados indol para uso en medicina. | |
JP2011150365A5 (es) | ||
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
ECSP21060240A (es) | Inhibidores de la pcsk9 y métodos de uso de los mismos | |
EA201100189A1 (ru) | Гетероарильные производные в качестве ингибиторов dgat1 | |
ECSP088431A (es) | Derivados de pirazolo | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
AR092749A1 (es) | Compuestos farmaceuticos | |
AR107135A1 (es) | Compuestos heterocíclicos y su uso en la prevención o en el tratamiento de infecciones bacterianas | |
ES2650372T3 (es) | Compuestos tricíclicos como inhibidores de CFTR | |
AR072200A1 (es) | Derivados dibenzotiazepina y usos de los mismos | |
AR057558A1 (es) | Compuestos de cinolincarboxamida y composicion farmaceutica | |
AR109774A1 (es) | Compuestos heterocíclicos y su uso en la prevención o el tratamiento de infecciones bacterianas | |
AR104543A1 (es) | Compuestos heterocíclicos y su uso en la prevención o el tratamiento de infecciones bacterianas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |